Director YOUNG JAMES F sold 12,500 shares of Novavax Inc. [NVAX]

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Novavax Inc. shares valued at $919,765 were sold by YOUNG JAMES F on Mar 31. At $73.58 per share, YOUNG JAMES F sold 12,500 shares. The insider’s holdings dropped to 62,590 shares worth approximately $3.88 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, Herrmann John A III sold 5,000 shares, netting a total of over 704,534 in proceeds. Following the sale of shares at $140.91 each, the insider now holds 3,845 shares.

Before that, YOUNG JAMES F had sold 3,750 shares from its account. In a trade valued at $540,601, the Director traded Novavax Inc. shares for $144.16 each. Upon closing the transaction, the insider’s holdings decreased to 3,750 shares, worth approximately $4.65 million.

As published in their initiating research note from BofA Securities on May 20, 2022, Novavax Inc. [NVAX] has been an Underperform and the price target has been revised to $35. This represents a -76.94% premium over Thursday’s closing price. Analysts at B. Riley Securities resumed the stock at ‘”a Buy”‘ outlook in a report released in late February. Earlier on January 21, 2022, Cowen initiated its rating. Their recommendation was “an Outperform” for NVAX stock.

Analyzing NVAX’s Price Performance

On Thursday, Novavax Inc. [NASDAQ: NVAX] rose 1.34% to $61.93. The stock’s lowest price that day was $60.01, but it reached a high of $63.2361 in the same session. During the last five days, there has been a surge of approximately 8.44%. Over the course of the year, Novavax Inc. shares have dropped approximately -56.71%. Shares of the company reached a 52-week high of $145.20 on 01/03/22 and a 52-week low of $34.88 on 06/13/22. A 50-day SMA is recorded $53.47, while a 200-day SMA reached $96.41. Nevertheless, trading volume fell to 3.32 million shares from 4.49 million shares the previous day.

Support And Resistance Levels for Novavax Inc. (NVAX)

According to the 24-hour chart, there is a support level at 60.21, which, if violated, would cause prices to drop to 58.50. In the upper region, resistance lies at 63.44. The next price resistance is at 64.95. RSI (Relative Strength Index) is 56.43 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 3.18, which suggests the price will increase in the coming days. Percent R is at 19.43%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Novavax Inc. subject to short interest?

Stocks of Novavax Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.74 million shares to 14.99 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 15.73 million shares. A decline of -4.94% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 1.91 of the overall float, the days-to-cover ratio (short ratio) decline to 1.91.

Which companies own the most shares of Novavax Inc. (NVAX)?

According to The Vanguard Group, Inc. filings, the company currently owns 6,868,884 shares, which is about 8.79% of the total NVAX shares outstanding. The investor’s shares have appreciated by 81,711 from its previous 13-F filing of 6787173.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $186,518,558. SSgA Funds Management, Inc. acquire a 31.40% interest valued at $128.35 million while Susquehanna Financial Group LLLP purchased a 93,648 stake. A total of 16,229 shares of Novavax Inc. were bought by Geode Capital Management LLC during the quarter, and 883,446 by Coatue Management LLC. In its current portfolio, Morgan Stanley & Co. LLC holds 698,629 shares valued at $35.93 million.

In terms of Novavax Inc. share price expectations, FactSet research, analysts set an average price target of $147.50 in the next 12 months, up nearly 162.64% from the previous closing price of $61.11. Analysts anticipate Novavax Inc. stock to reach $207.00 by 2022, with the lowest price target being $35.00. In spite of this, 7 analysts ranked Novavax Inc. stock as an Overweight at the end of 2022. On May 12, 2021, JP Morgan assigned a price target of “a Neutral” to the stock and downgraded coverage with a $161.

LEAVE A REPLY

Please enter your comment!
Please enter your name here